Dermapharm Holding SE (ETR:DMP)
Germany · Delayed Price · Currency is EUR 46.20
0.00 (0.00%)
May 8, 2026, 5:35 PM CET
Dermapharm Holding SE Earnings Call Transcripts
Fiscal Year 2025
-
Revenue and adjusted EBITDA for 2025 met guidance, with margin improvements and strong cash flow. Growth is expected in 2026 from M&A, branded products, and international expansion, while restructuring and portfolio optimization continue to drive efficiency.
-
Branded pharmaceuticals drove growth in Q3 2025, with strong international and Alargo Pharma performance. Portfolio optimization and restructuring improved margins, while guidance for full-year revenue and EBITDA is expected to be met, supported by seasonal strength in Q4.